Michael J Peluso1, Victor Valcour, Nittaya Phanuphak, Jintanat Ananworanich, James L K Fletcher, Thep Chalermchai, Shelly J Krebs, Merlin L Robb, Joanna Hellmuth, Magnus Gisslén, Henrik Zetterberg, Serena Spudich. 1. aDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts bDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, California, USA cSEARCH, The Thai Red Cross AIDS Research Center, Bangkok, Thailand dUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring eHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland , USA fDepartment of Infectious Diseases, Institute of Biomedicine, Gothenburg gDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden hUniversity College London Institute of Neurology, London, UK iYale University School of Medicine, New Haven, Connecticut, USA.
Abstract
OBJECTIVE: To characterize cerebrospinal fluid (CSF) YKL-40, a unique biomarker that reflects activation of microglial cells, in acute (AHI) and chronic HIV-1 infection (CHI) and to determine the effect of treatment initiation on levels of this marker. DESIGN: A cross-sectional study of two groups of HIV-infected participants at baseline and follow-up timepoints. METHODS: AHI (n = 33) and CHI (n = 34) participants underwent CSF and blood sampling before treatment initiation with combination antiretroviral therapy (cART) and at follow-up on cART in a subset of these individuals [6 months in AHI participants (n = 24), 1 year in CHI participants (n = 10)]. Measured parameters were analyzed at each timepoint. Analyses employed Mann-Whitney tests and Spearman correlations. RESULTS: Baseline median YKL-40 was higher in CHI than AHI (96844 versus 80754 ng/l; P = 0.011). Elevations in the CHI group relative to the AHI group persisted at follow-up despite treatment (87414 versus 66130 ng/l; P = 0.003). In untreated CHI, YKL-40 correlated with neopterin (r = 0.51, P = 0.0025), chemokine (CXC-motif) ligand-10 (r = 0.44, P = 0.011), and neurofilament light chain (r = 0.56, P = 0.0008) in CSF. CONCLUSIONS: This study is the first to describe the dynamics of CSF YKL-40 in two groups of HIV-infected individuals before and after cART and demonstrates the value of this marker in understanding HIV neuropathogenesis. The results suggest the utility of further exploring the prognostic value of YKL-40, particularly in individuals with early HIV infection or those initiating treatment during CHI.
OBJECTIVE: To characterize cerebrospinal fluid (CSF) YKL-40, a unique biomarker that reflects activation of microglial cells, in acute (AHI) and chronic HIV-1 infection (CHI) and to determine the effect of treatment initiation on levels of this marker. DESIGN: A cross-sectional study of two groups of HIV-infectedparticipants at baseline and follow-up timepoints. METHODS: AHI (n = 33) and CHI (n = 34) participants underwent CSF and blood sampling before treatment initiation with combination antiretroviral therapy (cART) and at follow-up on cART in a subset of these individuals [6 months in AHI participants (n = 24), 1 year in CHI participants (n = 10)]. Measured parameters were analyzed at each timepoint. Analyses employed Mann-Whitney tests and Spearman correlations. RESULTS: Baseline median YKL-40 was higher in CHI than AHI (96844 versus 80754 ng/l; P = 0.011). Elevations in the CHI group relative to the AHI group persisted at follow-up despite treatment (87414 versus 66130 ng/l; P = 0.003). In untreated CHI, YKL-40 correlated with neopterin (r = 0.51, P = 0.0025), chemokine (CXC-motif) ligand-10 (r = 0.44, P = 0.011), and neurofilament light chain (r = 0.56, P = 0.0008) in CSF. CONCLUSIONS: This study is the first to describe the dynamics of CSF YKL-40 in two groups of HIV-infected individuals before and after cART and demonstrates the value of this marker in understanding HIV neuropathogenesis. The results suggest the utility of further exploring the prognostic value of YKL-40, particularly in individuals with early HIV infection or those initiating treatment during CHI.
Authors: Rebecca L Dunfee; Elaine R Thomas; Paul R Gorry; Jianbin Wang; Joann Taylor; Kevin Kunstman; Steven M Wolinsky; Dana Gabuzda Journal: Proc Natl Acad Sci U S A Date: 2006-10-02 Impact factor: 11.205
Authors: Malin Wennström; Yulia Surova; Sara Hall; Christer Nilsson; Lennart Minthon; Oskar Hansson; Henrietta M Nielsen Journal: PLoS One Date: 2015-08-13 Impact factor: 3.240
Authors: Patrick H Maduna; Matt Dolan; Lwando Kondlo; Honey Mabuza; Judith N Dlamini; Mike Polis; Thabo Mnisi; Susan Orsega; Patrick Maja; Lotty Ledwaba; Thuthukile Molefe; Phumelele Sangweni; Lisette Malan; Gugu Matchaba; Paul Khabo; Greg Grandits; James D Neaton Journal: PLoS One Date: 2015-04-09 Impact factor: 3.240
Authors: Sahra Abdulle; Asa Mellgren; Bruce J Brew; Paola Cinque; Lars Hagberg; Richard W Price; Lars Rosengren; Magnus Gisslén Journal: J Neurol Date: 2007-04-10 Impact factor: 6.682
Authors: Maartje I Kester; Charlotte E Teunissen; Courtney Sutphen; Elizabeth M Herries; Jack H Ladenson; Chengjie Xiong; Philip Scheltens; Wiesje M van der Flier; John C Morris; David M Holtzman; Anne M Fagan Journal: Alzheimers Res Ther Date: 2015-09-17 Impact factor: 6.982
Authors: Jan Jessen Krut; Tomas Mellberg; Richard W Price; Lars Hagberg; Dietmar Fuchs; Lars Rosengren; Staffan Nilsson; Henrik Zetterberg; Magnus Gisslén Journal: PLoS One Date: 2014-02-11 Impact factor: 3.240
Authors: Katherine M Clifford; Vishal Samboju; Yann Cobigo; Benedetta Milanini; Gabriel A Marx; Joanna M Hellmuth; Howard J Rosen; Joel H Kramer; Isabel E Allen; Victor G Valcour Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Joanna Hellmuth; Bonnie M Slike; Carlo Sacdalan; John Best; Eugene Kroon; Nittaya Phanuphak; James L K Fletcher; Peeriya Prueksakaew; Linda L Jagodzinski; Victor Valcour; Merlin Robb; Jintanat Ananworanich; Isabel E Allen; Shelly J Krebs; Serena Spudich Journal: J Infect Dis Date: 2019-11-06 Impact factor: 5.226
Authors: Tammaryn Lashley; Jonathan M Schott; Philip Weston; Christina E Murray; Henny Wellington; Ashvini Keshavan; Sandrine C Foti; Martha Foiani; Jamie Toombs; Jonathan D Rohrer; Amanda Heslegrave; Henrik Zetterberg Journal: Dis Model Mech Date: 2018-05-08 Impact factor: 5.758
Authors: Tuula K Outinen; Paula Mantula; Pia Jaatinen; Mari Hämäläinen; Eeva Moilanen; Antti Vaheri; Heini Huhtala; Satu Mäkelä; Jukka Mustonen Journal: Viruses Date: 2019-08-21 Impact factor: 5.048